anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain an antimicrobial agent high in dermal safety and superior in storage stability, exhibiting high antibacterial power against Gram-positive bacteria, by making the agent include a specific hydrochalcone derivative as active ingredient. SOLUTION: This antimicrobial agent is obtained by including a hydrochalcone derivative of the formula [R<1> to R<4> are each H or COR (R is a 1-20C alkyl)] as active ingredient [e.g. 1,3-bis(2,4-dihydroxyphenyl)propane]. The derivative of the formula can be obtained, for example, by extraction/ purification from Dioscorea Composita. The amount of the derivative of the formula to be formulated is pref. 0.0005-10.0 wt.% based on the whole amount of this antimicrobial agent. This agent is applicable, pref. to Propionibacterium acnes and the like, being hopeful of the prevention/treatment of cutaneous bacterial infectious diseases caused by Gram-positive bacteria, especially pimple.
This study compares the effects of a standard smoking cessation treatment, including one-time brief counseling and provision of nicotine patch plus an 8-week moderate intensity exercise program versus the same standard smoking cessation treatment plus equivalent contact control among 60 healthy women. A number of techniques will be used to increase compliance with the treatment program, thus more effectively isolating the effects of exercise. These include: (1) a two-week run-in period prior to randomization; (2) use of behavioral contracting prior to participant randomization; and (3) performance of all exercise on-site. Smoking cessation outcomes (continuous abstinence and point prevalence abstinence) will be verified by carbon monoxide and saliva cotinine. Physical activity will be evaluated by attendance at the supervised sessions. We hypothesize that participants in the smoking cessation plus moderate intensity exercise condition will be more likely to quit smoking than participants in the smoking cessation treament plus contact control condition.
HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
In the method, a series of experiments is performed in order to explore a set of process parameter ranges and/or a set of ingredient ranges of a pharmaceutical processing system. The method comprises step 180, in which a set of process parameter ranges and/or a set of ingredient ranges is selected. In step 182 the series of experiments is run automatically in an integrated continuous pharmaceutical product processing system, in which the set of process parameter ranges and/or said set of ingredient ranges are explored. Measurement data is collected during the experiments taking into account the process dynamics in step 184. In step 186, a set of quality attributes is evaluated relative to at least one target attribute and/or quality attribute of a predetermined set of target attributes and/or quality attributes of a product, respectively. Finally, in step 188, the measurement data is stored. There may be an additional step 190 of adjusting at least one range of said set of process parameter ranges and/or said set of ingredient ranges during the series of experiments in response to differences between said set of target attributes and/or said set of quality attributes and the predetermined set of target attributes and/or quality attributes, respectively.
Etripamil is a calcium channel blocker currently in Phase 3 trials for the treatment of paroxysmal supraventricular tachycardia (PSVT). Systemic and local toxicity following once-weekly intranasal administration of etripamil was evaluated in cynomolgus macaques to support clinical development. Groups of animals (N = 8, 4 males and 4 females) were administered etripamil into the left nostril weekly at dose levels of 0 (vehicle), 1.9, 3.8, or 5.7 mg/kg/dose for 26 doses. Persistence, reversibility, and progression of findings were examined following a 28-day recovery period. Clinical signs were transient and were related to the intranasal administration (e.g., nasal discharge, sneezing, etc.) of etripamil. There were no macroscopic or systemic microscopic findings at any dose. Etripamil-related adaptive and reactive local changes affecting the nasal cavity, larynx, and nasopharynx were observed at ≥1.9 mg/kg/dose. Minimal to severe dose-dependent nasal epithelial damage was observed, mainly affecting respiratory and transitional epithelium. Following the 28-day recovery period, microscopic changes were confined to the left nasal cavity and nasopharynx. These changes were significantly lower in incidence and severity, with noticeable reversal of the adaptive and reactive changes, indicating partial to complete recovery of the epithelial lining. Based on the lack of systemic toxicity and the minimal and transient nasal changes, the systemic, no observable adverse effect level (NOAEL) of etripamil in monkeys was the high dose, 5.7 mg/kg/dose. The NOAEL for local toxicity was 1.9 mg/kg/dose. Collectively, these data support further study of etripamil in human trials as a potential treatment for PSVT.
Understanding the rate of lymphocyte replication and destruction in HIV infected patients, as well as the effects of therapy on lymphocyte replication should lead to a better understanding of the mechanisms behind the immunodeficiency induced by HIV. To examine this directly, up to 85 HIV-infected patients will be enrolled in the study. Patients will receive up to two 30 minute infusions (at least one month apart) of bromodeoxyuridine (BrDU; 200 mg/m(2)), an analogue of thymidine. BrDU is incorporated into DNA and can be measured using an anti-BrDU monoclonal antibody. It can be measured in subpopulations of cells to determine the rate of replication of those cells. All participants in this study will be reimbursed for the inconvenience and discomfort associated with study participation.
Portability of trans-ancestral polygenic risk scores is often confounded by differences in linkage disequilibrium and genetic architecture between ancestries. Recent literature has shown that prioritizing GWAS SNPs with functional genomic evidence over strong association signals can improve model portability. We leveraged three RegulomeDB-derived functional regulatory annotations-SURF, TURF, and TLand-to construct polygenic risk models across a set of quantitative and binary traits highlighting functional mutations tagged by trait-associated tissue annotations. Tissue-specific prioritization by TURF and TLand provide a significant improvement in model accuracy over standard polygenic risk score (PRS) models across all traits. We developed the Trans-ancestral Iterative Tissue Refinement (TITR) algorithm to construct PRS models that prioritize functional mutations across multiple trait-implicated tissues. TITR-constructed PRS models show increased predictive accuracy over single tissue prioritization. This indicates our TITR approach captures a more comprehensive view of regulatory systems across implicated tissues that contribute to variance in trait expression.
A computer-implemented method and system are provided for interventional radiology (IR). The method and system store multiple structured reports associated with corresponding IR procedures. Multiple anatomical atlases are stored that correspond to separate vascular districts. The method and system collect IR data corresponding to a select IR procedure and a vascular district of interest and obtain a candidate anatomical atlas from the multiple anatomical atlases based on the IR data. The candidate anatomical atlas illustrates the vascular district model associated with the select IR procedure. The method and system create a structured report based on the collected IR data, the structured report including the candidate anatomical atlas illustrating the vascular district model associated with the select IR procedure.
Patients in Stage IV Extrapulmonary Arm IX receive cycles 5-13 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
The invention relates to managing and processing of digitalized copy of human genome, which falls into the field of bioinformatics. The subject-matter of the invention is a set of mutually related computer implemented methods focused on solving privacy issues related to storage and sharing of the genome - the ultimate identifier of an individual. More specifically the invention masks personal information contained in raw genomic data, while preserving valuable properties of these data for further research. The personal information is stored in easily manageable confidential file generated by the invention. Moreover, the whole genome or its specific regions can be unmasked with this file for later examination of an unaltered genome for specific biological trait, which is standard procedure in personalized medicine. The confidential file is intended to be stored in a private device or in a trusted institution and remain in a possession of genome owner. Masked genomic data can be stored in public place so it remains available to all interested parts: the owner, medical units, researchers.
INTRODUCTION: Stiff neck is a condition mainly characterised by persistent pain and limited neck movement, which can substantially impact patients' daily lives during acute episodes. Accordingly, rapid pain relief and restoration of normal activities are the main needs of patients during doctor visits. This study aims to assess the immediate efficacy of acupuncture combined with active exercises in rapidly relieving pain and improving movement disorders within 10 min in patients with acute stiff neck (ASN).
METHODS AND ANALYSIS: This randomised controlled clinical trial is being conducted at a single centre in China. 120 participants diagnosed with ASN will randomly be assigned in a 1:1:1 ratio to one of three groups: the acupuncture combined with active exercise group (group A), sham acupuncture combined with active exercise group (group B) and active exercise only group (group C). Each participant will undergo a single 10 min session. The primary outcome is the effective rate at 10 min of treatment. Secondary outcomes include the effective rate at other time points (0-1, 2, 4, 6 and 8 min), Visual Analogue Scale score and cervical range of motion. The intention-to-treat analysis will include all randomised participants.
ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee of the Second Affiliated Hospital of Yunnan University of Chinese Medicine (2022-009). Written informed consent will be obtained from all participants before randomisation. The findings of this study will be disseminated through publication in a peer-reviewed journal and presentation at conferences.
TRIAL REGISTRATION NUMBER: ChiCTR2200066997.
No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
The Medical Laboratory Schenk-Ansorge Magdeburg Saxony-Anhalt Germany receives all blood samples of outpatient patients of the medical practices of the metropolitan area Magdeburg Saxony-Anhalt Germany. Every patient has a lifetime identification number Independent of the submitting practice. Every submitting medical doctor has a lifetime identification number and is identified by her/his medical subject /specialization. This analysis is based on that laboratory database. For that study a cohort of 1.031.336 patients from 12/2004 to 08/2014 is evaluated, that had been received blood tests with measurement of serum creatinine. For every serum creatinine an eGGR is calculated with the guideline recommended formula.
The present disclosure provides prophylactic nasal and throat sprays that can be used to prevent initial infection of COVID19, its more contagious variants, and other respiratory viral infections, and the methods of making of the same. Data is given in a series of embodiments that show how niclosamide from one supplier (AK Sci), who's initial powder has a block-like morphology of what appears to be a high solubility polymorph, readily dissolves in pH buffers providing increased amounts in solution as the solution pH is increased. Unlike more conventional particulate drug materials, this provides 20 uM to 30 uM solutions of niclosamide at pH 8 for a prophylactic, preventative nasal spray that has rapid permeation through the nasal mucin and direct access to the underlying epithelial cells that the virus infects. At higher pH of 9.2 it can provide a 300 uM solution of niclosamide for throat spray to be used at first signs of early infection. Another embodiment shows that niclosamide from a second supplier (Sigma), that already contains some of the low solubility most stable polymorph (the monohydrate) gives an initial dissolution (3 hrs) that is similar to the AK Sci material, overnight stirring converts the powdered excess niclosamide to the more stable and lower solubility polymorph. A further embodiment shows how niclosamide from commercially available tablets (Yomesan) can be extracted into aqueous pH solution that does not involve the use of organic solvents. Additional embodiments show a solvent injection technique can be used to make supersaturated solutions of niclosamide that eventually precipitate and also form the low solubility monohydrate polymorph as do water, acetone, and ethanol niclosamide cosolvates. The solvent injection technique is the preferred method to make niclosamide solutions at concentrations where it is soluble because the initial powdered material can be dissolved in ethanol, any microparticulate impurities filtered out, and a clear solution made that is not in contact or equilibrium with any powdered material, that if it forms the monohydrate polymorph would reduce the amount of niclosamide in solution and therefore reduce its bioavailability to the nasal and respiratory epithelium.
Intestinal ischemia/reperfusion (I/R) injury is a life-threatening condition with no effective treatment currently available. Curcumin (CCM), a polyphenol compound in Curcuma Longa, reportedly has positive effects against intestinal I/R injury. However, the mechanism underlying the protective effect of CCM against intestinal I/R injury has not been fully clarified. To determine whether the protective effect of CCM was mediated by epigenetic effects on Wnt/β-catenin signaling, the effect of CCM was examined in vivo and in vitro. An intestinal I/R model was established in Sprague-Dawley (SD) rats with superior mesenteric artery occlusion, and Caco-2 cells were subjected to hypoxia/reoxygenation (H/R) for in vivo simulation of I/R. The results showed that CCM significantly reduced inflammatory, cell apoptosis, and oxidative stress induced by I/R insult in vivo and in vitro. Western blot analysis showed that CCM preconditioning reduced the protein levels of β-catenin, p-GSK3β, and cyclin-D1 and increased the protein level of GSK3β compared with the I/R group. Overexpressing β-catenin aggravated H/R injury, and knocking down β-catenin relieved H/R injury by improving intestinal permeability and reducing the cell apoptosis. Moreover, Naked cuticle homolog 2(NKD2) mRNA and protein levels were upregulated in the CCM-pretreated group. 5-aza-2'-deoxycytidine (5-AZA) treatment improved intestinal epithelial barrier impairment induced by H/R. Besides, the protein levels of total β-catenin, phosphor-β-catenin and cyclin-D1 were reduced after overexpressing NKD2 in Caco-2 cells following H/R insult. In conclusion, Our study suggests that CCM could attenuate intestinal I/R injury in vitro and in vivo by suppressing the Wnt/β-catenin signaling pathway via inhibition of NKD2 methylation.
EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
When elderly people want to live in their own homes, an important issue arises: loneliness. Loneliness is a common problem among older adults and has become increasingly common in recent years. Loneliness not only affects psychological well-being, but also negatively affects physical health, increasing the likelihood of illness and death.When people live longer, they are more likely to experience health problems such as physical weakness, cognitive decline, and chronic diseases. Weakness among older people creates a state of vulnerability that increases the risk of adverse health outcomes, leading to reduced daily activities and the need for long-term care.This study aims to develop healthy lifestyle behaviors, reduce loneliness levels and increase social support capacity of elderly people living alone at home.The research was planned as a quasi-experimental research. The research population consists of elderly people living alone at home who are registered to the Elderly and Home Care Unit of a Municipality of a province. Elderly people who are registered to a home care unit, live alone, and are over the age of 65 and agree to work will be included in the research. Individuals under the age of 65 and those with mental disabilities will be excluded from the study. The independent variable of the research is; The status of receiving a home visit supported nurse care program was determined as the dependent variable of the study: Healthy Lifestyle Behaviors Scale II score, loneliness scale score, social support scale score.
<P>PROBLEM TO BE SOLVED: To quickly display a medical image without receiving a large quantity of useless data through a communication line.  <P>SOLUTION: The medical image processing apparatus 11 comprises a data processing means, a voxel data transfer requesting means, a voxel data receiving means, and an image display means. The medical image processing apparatus 11 also has a voxel data accumulation means 112 and an accumulation history 3D mask data accumulation means 113. The data processing means specifies voxels necessary for displaying a required image, refers to the accumulation history 3D mask data accumulation means 113 for whether the image data are accumulated in each specified voxel, and transfers the voxel specifying information yet to be stored, as the result of reference to the accumulation history 3D mask data accumulation means 113, to the voxel data transfer request means. Then, the voxel data transfer request means transfers the unaccumulated voxel specifying information as the result of reference transferred from the data processing means to the data server 12 side.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Patients with end-stage renal disease (ESRD) have a 20-fold increased risk of cardiovascular mortality compared to the general population. Arterial stiffness, likely due to vascular calcification (VC), has been shown to predict cardiovascular mortality in ESRD. Serum calcification propensity (T50) is a novel biomarker, which is believed to reflect the propensity toward ectopic calcification (e.g. VC). Increasing serum magnesium (sMg) should increase T50, which might in turn reduce the formation of VC in patients with ESRD. A cheap and easy way of achieving this would be to increase the concentration of Mg in the dialysate (dMg) of patients with ESRD treated with haemodialysis (HD).

The investigators wish to conduct a randomised controlled double-blind clinical trial to examine whether increasing dMg will improve T50 in subjects with ESRD treated with HD.
There is no specific antidote for doxapram. Management should be symptomatic. Anticonvulsants, along with oxygen and resuscitative equipment should be readily available to manage overdosage manifested by excessive central nervous system stimulation. Slow administration of the drug and careful observation of the patient during administration and for some time subsequently are advisable. These precautions are to assure that the protective reflexes have been restored and to prevent possible post-hyperventilation or hypoventilation.

There is no evidence that doxapram is dialyzable; further, the half-life of doxapram makes it unlikely that dialysis would be appropriate in managing overdose with this drug.
The genetic alterations currently identified in papillary thyroid microcarcinomas (PTMCs) are insufficient for distinguishing tumors with aggressive features. We aimed to identify candidate markers associated with lateral lymph node metastasis (LLNM, N1sb disease) in patients with PTMC using transcriptomic analysis. RNA sequencing was performed on 26 matched tumor and normal thyroid tissue samples (N0, n = 14; N1b, n = 12), followed by functional enrichment analyses of differentially expressed genes (DEGs). EcoTyper was used to explore the distinct tumor microenvironment (TME). We identified 631 DEGs (213 upregulated and 418 downregulated) between N1b and N0 PTMCs. The most significantly upregulated genes in N1b were associated with tumorigenesis, adhesion, migration, and invasion. DEGs were mainly enriched in the pathways of idiopathic pulmonary fibrosis, TME, wound healing, and inhibition of matrix metalloproteases. We predicted the activation of these pathways in N1b PTMCs. N1b PTMCs had a unique TME with abundant fibroblasts and epithelial cells, associated with an increased risk of disease progression. Fibroblast marker genes, including POSTN, MMP11, TNFAIP6,and FN1, and epithelial cell marker genes, including NOX4, MFAP2, TGFVBI,and TNC, were selected. POSTN and FN1, fibroblast cell-specific genes, and NOX4 and TNC, epithelial cell-specific genes, were promising biomarkers for predicting LLNM development and recurrence in patients with PTMC. We delineated the cellular ecotypes within the TME of patients with N1b PTMC and revealed potential markers for predicting LLNM and the prognosis of PTMC. These findings provide valuable insights into the contributions of cancer-associated fibroblasts and epithelial cells to PTMC progression and metastasis.
The present invention can be used in pharmacology specifically in the preparation of interferon-containing compositions, which are capable of conserving their biological activity and can be administrated intranasally, e.g. in the preparation of nasal drops. This invention essentially refers to an antiviral agent in the form of nasal drops that contains a genetically engineered alpha, beta or gamma interferon with a viscosity of (1.1 - 30.0) * 10 Pa*s, a biocompatible polymer and a buffer mixture. The agent may further include an antioxidant, and the ingredients are contained in the following amounts per ml buffer mixture: 1,000 to 500,000 IU  of genetically engineered interferon; 0.005 to 0.714 g of biocompatible polymer; and 0.0001 to 0.0008 g of an antioxidant. Trilon B.TM. is used as the antioxidant, whereas polyvinilpyrrolidone and/or polyethylene oxide is (are) used as the biocompatible polymer(s) at polyvinilpyrrolidone/  polyethylene oxide ratio is 1:1 - 50.
Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.